You are viewing a free summary from Descrybe.ai. For citation checking, legal issue analysis, and other advanced tools, explore our Legal Research Toolkit — not free, but close.

Federal Trade Commission v. Quincy Bioscience Holding Co.

Citation: 272 F. Supp. 3d 547Docket: 17 Civ. 124 (LLS)

Court: District Court, S.D. New York; September 28, 2017; Federal District Court

Narrative Opinion Summary

In this case, the Federal Trade Commission (FTC) and the State of New York pursued legal action against Quincy Bioscience Holding Company, Inc., its subsidiaries, and individual defendants, alleging violations of deceptive advertising laws. The allegations centered on claims regarding the dietary supplement Prevagen's effectiveness, which were purportedly based on the Madison Memory Study. The plaintiffs contested the validity of the study's subgroup analyses, arguing that they were not reliable evidence of the supplement's benefits and that the representations made in advertising were misleading. The defendants moved to dismiss the complaint, asserting that it failed to establish a valid legal claim, lacked personal jurisdiction over individual defendants, and constituted an unconstitutional restraint on commercial speech. The court found that the complaint did not present sufficient factual matter to suggest the representations were false or misleading according to the FTC Act's standards. Consequently, the federal claims were dismissed, leading the court to decline supplemental jurisdiction over the state law claims, which were dismissed without prejudice. The decision effectively concluded the federal aspects of the case, leaving any remaining state claims to be pursued in New York courts.

Legal Issues Addressed

Deceptive Advertising under FTC Act

Application: The court examined whether the defendants' advertising claims about Prevagen's effectiveness were false or misleading under the FTC Act.

Reasoning: They cite violations of several laws, including the FTC Act regarding deceptive practices... A violation of the FTC Act necessitates proof of (1) a representation, omission, or practice, (2) likely to mislead reasonable consumers, and (3) materiality.

Motion to Dismiss Standards

Application: The court applied the standard for a motion to dismiss, requiring the complaint to present sufficient factual matter to establish a plausible claim for relief.

Reasoning: To survive a motion to dismiss, a complaint must present sufficient factual matter to establish a plausible claim for relief. The standard requires more than mere labels or conclusions; it demands factual content that permits a reasonable inference of liability.

Personal Jurisdiction in Civil Cases

Application: The defendants challenged the personal jurisdiction over individual defendants, but the court ultimately dismissed the case on other grounds without deciding this issue.

Reasoning: Defendants, including Quincy Bioscience Holding Company, Inc. and its subsidiaries, along with individual defendants Mark Underwood and Michael Beaman, have filed motions to dismiss the complaint, claiming it fails to state a valid legal claim and challenging personal jurisdiction over Beaman and Underwood.

Supplemental Jurisdiction under 28 U.S.C. § 1367(c)(3)

Application: With the dismissal of federal claims, the court declined to exercise supplemental jurisdiction over state law claims, suggesting they be addressed by New York courts.

Reasoning: With the dismissal of federal law claims, there is insufficient basis for exercising supplemental jurisdiction over state law claims, leading to a decision to decline jurisdiction as per 28 U.S.C. § 1367(c)(3).

Unconstitutional Restraint on Commercial Speech

Application: Defendants argued the requested relief would constitute an unconstitutional restraint on commercial speech, but the court dismissed the case on other grounds.

Reasoning: Defendants seek to dismiss the complaint on several grounds... (3) the requested relief constitutes an unconstitutional restraint on commercial speech...